Every big-dog owner learns the same unfair math eventually. A Great Dane or a Saint Bernard, all that heart packed into all that body, often gets seven or eight years. A Chihuahua can stroll past fifteen. Same species, wildly different clocks, and for once the little guy wins.
A biotech company named Loyal is betting that gap is not a fact of nature so much as a side effect of how we built these dogs, and that a drug might close some of it. What follows is the honest version: what the science is actually doing, why it is a genuinely big deal, and the parts that are still years from proven.
Start with the puzzle: why big dogs die young
Across most of the animal kingdom, bigger bodies live longer. Elephants outlast mice. Dogs break that rule and run it backward. Within a single species, the largest breeds tend to have the shortest lifespans, and nobody chose that on purpose. It is the accumulated cost of a couple hundred years of breeding dogs to be huge.
One suspect keeps coming up: a growth hormone called insulin-like growth factor 1, or IGF-1. Big dogs carry more of it, and IGF-1 does not just drive body size, it appears to be tangled up in the pace of aging. In lab studies, dialing IGF-1 down has extended the lifespan of worms, flies, and rodents. In people, the lowest mortality tracks with a middle-of-the-road level, not a high one.
What the drug actually does
Loyal’s large-dog candidate, called LOY-001, is designed to lower IGF-1 in big dogs and to blunt the insulin spikes that tend to climb as a dog ages. It is not a pill you give at symptom onset. It is an injection given every three to six months, aimed at the aging process before things go wrong, which is a genuinely different philosophy from almost every drug in a vet’s cabinet.
In late 2023, the U.S. Food and Drug Administration determined that Loyal had shown a “reasonable expectation of effectiveness” for the drug. That phrase is doing a lot of work, so read it carefully. It means the agency accepted the theory as plausible enough to keep going. It does not mean the drug is approved, and it does not mean anyone has yet proven it makes a single dog live longer. So far the reported side effects have been mild and temporary, mostly short-lived stomach upset in the days after an injection.
The claim, kept honest
Loyal’s founder, Celine Halioua, has been unusually clear that this is not an immortality project. The goal she describes is not adding decades but “rounding out the curve,” stretching the healthy, good-quality years and compressing the long slow decline at the end. Roughly one extra year is the target the company talks about, which for a breed that only gets eight is not nothing.
Company scientists frame the short lives of giant breeds not as destiny but as a problem we created through selective breeding, and therefore something a medicine might be able to treat. You are allowed to find that framing either inspiring or unsettling. Both reactions are reasonable.
“What makes this interesting to me as a vet is the shift from treating diseases to treating the thing underneath the diseases,” says Dr. Ravi Mehta. “That said, I’d tell any owner the same thing: a regulatory milestone is a green light to keep studying, not proof it works. Extending a dog’s healthy years still starts with the boring, proven stuff, weight control, dental care, and regular checkups.”
What’s new since this was written
Since the original large-dog announcement, Loyal has pushed a second, related drug further down the field. LOY-002, a daily flavored tablet for senior dogs aged ten and up weighing at least fourteen pounds, has been clearing the FDA’s technical sections one at a time. The agency accepted its effectiveness section in early 2025 and its target-animal-safety section in early 2026, which puts it two of three major hurdles down toward a possible conditional approval and market launch.
None of that is a promise. A conditional approval, if it comes, lets a drug be sold by prescription while the company keeps collecting data toward full approval. The honest summary in 2026 is the same as it was in 2023, just further along: the regulatory path is moving, the long-term proof is still being gathered, and no dog owner should treat any of this as available medicine yet.
The bottom line for your dog
If you share your life with a big dog, this research is worth watching and worth zero panic-buying. There is nothing to purchase, and the best longevity plan available to you today has not changed: keep your dog lean, keep their teeth clean, keep up with veterinary care, and enjoy the years you have. If a safe drug ever adds one more good one, that will be a gift on top of a foundation you built yourself.
References
- FDA/Loyal via Business Wire: FDA Agrees Loyal Data Supports Reasonable Expectation of Effectiveness for Large Dog Lifespan Extension
- Business Wire: Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness for Senior Dog Lifespan Extension
- dvm360: FDA determines drug for lifespan extension in large dogs to have a Reasonable Expectation of Effectiveness
- University of Melbourne Pursuit: Why do small dogs live longer than big dogs?
